
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.
All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.
Disclosure information is available at the beginning of the video presentation.
4.5
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.
All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.
Disclosure information is available at the beginning of the video presentation.
1,794 Listeners
319 Listeners
40 Listeners
28 Listeners
10 Listeners
529 Listeners
5 Listeners
4 Listeners
2 Listeners
4 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
116 Listeners
12 Listeners
2 Listeners
4 Listeners
57 Listeners
3 Listeners
5 Listeners
289 Listeners
21 Listeners
190 Listeners
53 Listeners
56 Listeners
49 Listeners
185 Listeners
43 Listeners